Technology
The NovaPLEX family of technology is founded on unique proprietary chemistry to address the drivers the of genetic analysis market, namely
- Use of new sample types, quantities, and form
- Greater sensitivities and faster protocols
- Improved workflows and automation
- Lower cost per result outcome
| PicoPLEX | OmniPLEX | ThruPLEX | |
|---|---|---|---|
| Chemistry Principle | Prepares pg input DNA samples or whole cells (e.g. single human cells) for PCR and microarray analysis using a cell lysis and thermal cycling library synthesis followed by extreme low background amplification. |
Prepares ng input purified DNA/RNA samples for PCR and microaarray analysis using an isothermal, quasi-random primed library synthesis followed by low background amplification. |
Prepares pg to ng fragmented DNA or cDNA for NGS analysis using multiplexed enzyme reactions for efficient repair and blunt end ligataion library synthesis followed by high fidelity amplification. |
| Applications |
- IVF: PGS/PGD |
- Fixed/frozen tissue (cancer) |
- Fixed/frozen tissue (cancer) |
| Commercial Products |
GenomePLEX WGA (Offer by Sigma for Research Only) TransPLEX WTA (Offer by Sigma for Research Only) |
||
| History |
Patent pending. PicoPLEX is currently commercialized as PicoPLEX Single-Cell WGA kits. Launched in 2009, these kits have become the gold standard for genetic testing of human and livestock embryos, polar bodies, sperm, and trophectoderm to support of in vitro fertilization, including pre-implantation screening and diagnosis. |
Protected by US Patent 7,718,403; EP1604040. OmniPLEX technology is currently commercialized as GenomePLEX® C-WGA and TransPLEX® C-WTA kits. Launched in 2003 and 2004, these kits are used for human, animal, plant, and environmental diagnostic applications. |
Protected by US 7,803,550 and EP1924704. ThruPLEX is currently commercialized as ThruPLEX-FD Prep kits for high throughput, high-sensitivity NGS on Illumina platforms for both diagnostic and research applications. |
